Business
Helix BioPharma Corp. announces management changes
AURORA, ON, Nov. 15 /CNW/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced position chan...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, ON, Nov. 15 /CNW/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today\nannounced position changes for Dr. Donald Segal and John Docherty. Effective\nimmediately, the joint role of Chief Executive Officer and President formerly\nheld by Dr. Segal will be separated whereby Dr. Segal will remain the\nCompany's Chief Executive Officer and Mr. Docherty will assume the role of\nPresident.\n\n\n"These changes are being made as we strive to expand our corporate\ninitiatives, primarily in the U.S.A.," said Dr. Segal. "Moving forward, I am\npleased to have John take on added responsibilities so that I may increasingly\nfocus my time on growing our business by developing new financial, partnering\nand other strategic initiatives for the Company. John will concentrate on\nenhancing our public profile, overseeing our advancing clinical programs and\nmanaging our related day to day operations."\n\n\nDr. Segal and Mr. Docherty have a history of proven leadership with the\nCompany. Dr. Segal is a founding partner, serves on the board of directors and\nhad been Chief Executive Officer and President since 2004. Mr. Docherty joined\nthe Company in 1999 with degrees in toxicology and pharmacology and a\ncomprehensive background in pharmaceutical product and corporate development.\nAt Helix, Mr. Docherty has been instrumental in developing the Company's lead\nproduct candidate, Topical Interferon Alpha-2b, in addition to supporting the\nCompany's growing investor and media relations initiatives. Previously, Mr.\nDocherty served as Vice President, Corporate Development since 2002.\n\n\nAbout Helix BioPharma Corp.\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed\non the TSX under the symbol "HBP".\n\n\nThe Toronto and Frankfurt Stock Exchanges have not reviewed and do not\naccept responsibility for the adequacy or accuracy of the content of this News\nRelease. This News Release contains certain forward-looking statements and\ninformation regarding Helix's strategic, financi...